![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
[email protected]Shown: posts 1 to 1 of 1. This is the beginning of the thread.
Posted by sdb on March 30, 2009, at 7:56:39
i am curious if bopindolol could be of any value in the psychiatry since it resembles structurally its predecessor (one of the metabolites) pindolol and the effects at the 5-ht receptor seem to be similar too.
unfortunately there's no data in the US because it isn't on the market there.
what do you think about that?
bopindolol
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=50023190&loc=es_rss
pindolol
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=50023355&loc=es_rss
2.8. Bopindolol
Bopindolol is a nonselective h-blocker that has h2-
agonistic action (Brodde et al., 1986b) and interacts with
5-HT receptors (Nagatomo et al., 2001). In the perfused rat
kidney, i.a. bopindolol, but not propranolol, decreased
perfusion pressure and increased NO release, and the effects
were abolished by 5-HT1A receptor antagonists (Kakoki et
al., 1999). In anesthetized rats, i.v. bopindolol did not affect
total peripheral resistance but propranolol markedly increased
it. Blood flow in the brown fat was increased by
bopindolol (Takahashi et al., 2002). No changes were found
in the plasma concentrations of total cholesterol, LDL
cholesterol, and HDL cholesterol during long-term monotherapy
with bopindolol (Van Brummelen et al., 1984).
Plasma triglycerides were increased. It is suggested that
the potent antioxidant activity of this antagonist may produce
a beneficial effect for the treatment of ischemic heart
diseases (Aniya et al., 1995).
This is the end of the thread.
Psycho-Babble Neurotransmitters | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
[email protected]
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.